Holen Sie sich die Stockscreener-App
1.74
6.45%
-0.12
Handel nachbörslich:
1.74
Schlusskurs vom Vortag:
$1.86
Offen:
$1.8
24-Stunden-Volumen:
429.86K
Relative Volume:
1.37
Marktkapitalisierung:
$12.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.72M
KGV:
-0.6592
EPS:
-2.6394
Netto-Cashflow:
$-6.25M
1W Leistung:
-33.84%
1M Leistung:
-32.03%
6M Leistung:
-27.02%
1J Leistung:
-45.63%
1-Tages-Spanne:
$1.69
$2.0196
1-Wochen-Bereich:
$1.69
$2.38
52-Wochen-Spanne:
$1.55
$4.4899
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Vergleichen Sie EDSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
1.74 | 13.66M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
Edesa Biotech (EDSA) Receives Reiterated 'Buy' Rating from HC Wa - GuruFocus
Is Edesa Biotech Inc. stock affected by interest rate hikesWeekly Volume Report & Risk Managed Investment Strategies - newser.com
Has Edesa Biotech Inc. found a price floorWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Best data tools to analyze Edesa Biotech Inc. stock2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Edesa Biotech, Inc. (EDSA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Edesa Biotech to Participate in Key Industry Conferences - TipRanks
Edesa Biotech Announces Upcoming Conference Schedule - The Manila Times
Edesa Biotech (NASDAQ: EDSA) to attend BIO-Europe Vienna, LSX London in November 2025 - Stock Titan
Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock - simplywall.st
Is Edesa Biotech Inc. still worth holding after the dipMarket Trend Review & Technical Buy Zone Confirmations - newser.com
Will Edesa Biotech Inc. stock benefit from sector rotationQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Edesa Biotech Inc a good long term investmentMean Reversion Trades & Affordable Trading Portfolio - earlytimes.in
Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial - Investing.com Canada
EDSA’s Market Surge: Time to Jump In? - StocksToTrade
Edesa Biotech (EDSA) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial By Investing.com - Investing.com South Africa
EDSA’s Performance: What’s Driving the Change? - timothysykes.com
Edesa Biotech Reports Positive Phase 3 Results For Paridiprubart In ARDS - Nasdaq
Edesa Biotech reports positive Phase 3 results for ARDS drug candidate - Investing.com Nigeria
Edesa Biotech Announces Positive Phase 3 Study Results - TipRanks
Edesa Biotech Announces Positive Phase 3 Results for ARDS Treatment - TradingView
Edesa Biotech Announces Positive Phase 3 Results for Paridiprubart in Treating Acute Respiratory Distress Syndrome, Showing Significant Reduction in Mortality - Quiver Quantitative
[8-K] Edesa Biotech, Inc. Reports Material Event | EDSA SEC FilingForm 8-K - Stock Titan
Edesa Biotech (Nasdaq: EDSA) posts Phase 3 ARDS results: 25% lower death risk, recovery - Stock Titan
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study - Sahm
Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):